Wilson Disease Clinical Landscape Report 2026: Trials, Readouts and White Space
Turn fragmented clinical intelligence into a decision-ready landscape. This report was assembled with PatSnap MCP Servers for Clinical Trials, Drug & Asset, and Company & Deal Intelligence. Explore the PatSnap MCP Marketplace to reproduce the workflow in your own AI research stack.
Data snapshot: 16 July 2026. This report is a strategic research view, not medical advice. Trial status and timing can change; confirm records before making development or investment decisions.
Executive view
Wilson Disease remains an active clinical development field. One-time and precision therapies are raising the efficacy ceiling, but durability, manufacturing, small-population evidence and long-term safety remain decisive constraints. The PatSnap evidence set used here contains 58 matched trial records and 25 indexed result records before the decision-focused sample below was selected.
How PatSnap MCP built this report
The workflow used Clinical Trials MCP search to define the landscape, then clinical_trial_fetch to retrieve trial design, phase, status, sponsor, geography, endpoints and timing. It separately called clinical_trial_result_fetch for indexed readouts. Drug & Asset drug_fetch supplied target and global development status, while Company & Deal Intelligence organization_fetch supplied sponsor context. This keeps trial-, asset- and company-level claims distinct and traceable.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Expected readout |
|---|---|---|---|---|---|---|
| NCT07641140 | LY-M003 | Phase 1/2; Not yet recruiting | Lingyi (Hangzhou) Biotechnology Co., Ltd. | China | Phase I:The incidence of dose-limiting toxicity (DLT) events adjudicated by the Safety Review Committee (SRC) within at least 28 days after LY-M003 infusion. (Within 28 days after infusion of LY-M003 Injection); The incidence of treatment-emergent adverse events (AEs), adverse events of special interest (AESIs) and serious adverse events (SAEs) related to LY-M003 within 52 weeks after infusion. (5 years) | 2027-12-30 |
| ChiCTR2600126269 | LY-M003 | Phase 1/2; Not yet recruiting | Lingyi (Hangzhou) Biotechnology Co., Ltd.; The First Affiliated Hospital, Zhejiang University Sch of Med | China | Phase I:The incidence of dose-limiting toxicity (DLT) events adjudicated by the Safety Review Committee (SRC) within at least 28 days after LY-M003 infusion.; Phase I/II: The incidence of treatment-emergent adverse events (AEs), adverse events of special interest (AESIs) and serious adverse events (SAEs) related to LY-M003 within 52 weeks after infusion; and the incidence of abnormal findings in 12-lead ECG, vital signs (blood pressure, pulse, respiratory rate, body temperature), laboratory tests (blood routine, blood biochemistry, coagulation function, stool routine, urine routine) and physical examinations within 52 weeks after administration. | 2032-05-31 |
| NCT07465718 | Trientine tetrahydrochloride | Phase 3; Not yet recruiting | Orphalan SA | United States | Absolute value of serum NCC at Week 48 assessed using the NCC-speciation assay (serum NCC-Sp) (Week 48) | 2028-02-01 |
| NCT07301216 | Intervention not normalized | Not Applicable; Recruiting | Yale University | United States | Mean concentration of OT-UCE for each standard of care WD treatment (days 1, 2, 3 and 4 post stopping WD meds); Mean NCC concentration for each WD treatment (days 1, 2, 3 and 4 post stopping WD meds) | 2028-06-30 |
The table is designed for competitive decisions: endpoint selection, geographic reach and readout timing appear beside phase and sponsor. Phase alone does not reveal evidence maturity; a small study may answer a near-term biomarker question while a large pivotal program can leave a multi-year readout gap.
What indexed results say
- First-in-Pediatric Evaluation of LY-M003 for Wilson Disease: Safety and Early Evidence of Copper Metabolism and Neurological Restoration (Phase 1/2): the indexed record reports UWDRS neurological subscale score(24-week) = 13.0 point.
- A Phase I, Single Centre, Randomised, Interventional, Open-Label, Cross-Over Study to Evaluate the Pharmacokinetics (PK) and the Safety and Tolerability of a Total Daily Dose of 900mg of TETA 4HCL, Comparing a New Once Daily TETA 4HCL Formulation (300mg) (3x300mg Trientine Base Tablets, OD) With the Current Marketed Cuprior® Formulation (150mg) (3x150mg Trientine Base Tablets, BD) in Adult Healthy Male and Female Participants (Phase 1): the indexed record reports AUC(Geometric Mean) = 12668.493 h*ng/mL (90% Confidence Interval, 10236.595 - 15678.135); AUC(Geometric Mean) = 10971.720 h*ng/mL (90% Confidence Interval, 8865.542 - 13578.262); -.
- Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments (Not Applicable): the indexed record reports sustained clinical benefits = 2.63 year.
Cross-trial comparisons require caution. Population, prior therapy, baseline risk, endpoint definition, follow-up and analysis set can all change the apparent signal. The strategic value lies in identifying what each readout resolves—and which uncertainty remains.
Build a living clinical map: connect to PatSnap MCP Servers and combine trial design, result, asset and organization records without manually reconciling separate databases.
Asset and sponsor context
PatSnap Drug & Asset records add mechanism and global development status for the sampled programs, including LY-M003 (Phase 1/2; ATP7B), Trientine tetrahydrochloride (Approved). Company & Deal Intelligence records identify sponsor context for Lingyi (Hangzhou) Biotechnology Co., Ltd., The First Affiliated Hospital, Zhejiang University Sch of Med, Orphalan SA, Yale University. Together, those layers show whether a study sits inside a scaled portfolio, an emerging specialist strategy or an academic development path.
Where the white space is
- Natural-history-aligned endpoints that remain interpretable in small heterogeneous cohorts.
- Long-term registries for durability, immunogenicity and delayed safety signals.
- Redosing, rescue and treatment-sequencing strategies after incomplete response.
- Access models that address diagnosis, manufacturing and global delivery.
Strategic implications
For sponsors, differentiation is more credible when the evidence package resolves a known decision gap: an active comparator, a better-defined responder population, a safer or easier delivery model, a clinically meaningful outcome, or a defensible sequencing strategy. Business-development teams can use the same landscape to separate crowded mechanisms from differentiated evidence architectures. Investors should track endpoint maturity and operational feasibility alongside nominal phase.
What to monitor next
Track status changes, protocol amendments, primary-completion dates, newly indexed results, ownership changes and multinational expansion. Re-run the MCP queries on a schedule and compare deltas. Pay particular attention when a program moves from a surrogate endpoint to a clinical outcome or when a specialist sponsor adds a scaled development partner.
Bottom line
Wilson Disease has meaningful clinical activity and equally meaningful evidence gaps. A useful landscape connects trial design, results, mechanism and sponsor rather than listing studies in isolation.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and use Clinical Trials, Drug & Asset, and Company & Deal Intelligence as structured building blocks for monitoring and SEO-ready clinical reports.
